Production (Stage)
Xenon Pharmaceuticals Inc.
XENE
$29.75
-$0.74-2.43%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | 2.91% | 4.39% | |||
| Gross Profit | 9.71% | -4.39% | |||
| SG&A Expenses | 5.74% | 7.78% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 3.56% | 5.16% | |||
| Operating Income | 6.12% | -5.16% | |||
| Income Before Tax | 7.07% | -10.18% | |||
| Income Tax Expenses | 111.10% | -1,102.50% | |||
| Earnings from Continuing Operations | 0.97% | -4.61% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 0.97% | -4.61% | |||
| EBIT | 6.12% | -5.16% | |||
| EBITDA | 6.20% | -5.26% | |||
| EPS Basic | 1.36% | -4.00% | |||
| Normalized Basic EPS | 7.41% | -9.52% | |||
| EPS Diluted | 1.36% | -4.00% | |||
| Normalized Diluted EPS | 7.41% | -9.52% | |||
| Average Basic Shares Outstanding | 0.38% | 0.59% | |||
| Average Diluted Shares Outstanding | 0.38% | 0.59% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||